The author points out that whilst the total metabolic fate of phenylbutazone in man is better understood, discrepancies between single and multiple dose half-lives, as shown in the studies described, still remain to be explained. It is concluded that the mechanism responsible for limiting the plasma concentration of phenylbutazone when doses are increased requires further study.
Get full access to this article
View all access options for this article.
References
1.
AarbakkeJ, BakkeO M, MildeE J & DaviesD S (1977) The disposition and oxidative metabolism of phenylbutazone in man. European Journal of Clinical Pharmacology11, 359
2.
AarbakkeJ, BendingM R & DaviesD S (1977) Increased oxidation of phenylbutazone during hydrocortisone infusion in man. British Journal of Clinical Pharmacology (in press)
3.
BakkeO M, DraffanG H & DaviesD S (1974) The metabolism of phenylbutazone in the rat. Xenobiotica4, 237
4.
BurnsJ J, RoseR K, ChenkinT, GoldmannA, SchulertA & BrodieB B (1953) The physiological disposition of phenylbutazone (Butazolidin) in man and a method for its estimation in biological material. Journal of Pharmacology and Experimental Therapeutics109, 346
5.
BurnsJ J, RoseR K, GoodwinF, ReichenthalJ, HorningE C & BrodieB B (1953). The metabolic fate of phenylbutazone (Butazolidin) in man. Journal of Pharmacology and Experimental Therapeutics109, 481
6.
BreckenridgeA, BurkeC W, DaviesD S & OrmeM (1973) Immediate decrease by hydrocortisone of the plasma half-lives of antipyrine. British Journal of Pharmacology47, 434
7.
BrodieB B, LomanE W, BurnsJ J, LeeP R, ChenkinT, GoldmannA, WeinerM & SteeleJ M (1954) Observations of the anti-rheumatic and physiologic effects of phenylbutazone (Butazolidin) and some comparisons with cortisone. American Journal of Medicine16, 181
8.
BruckE, FearnleyM E, MeanockI & PatleyH (1954) Phenylbutazone therapy. Relationship between toxic and therapeutic effect and the blood level. Lancet la, 225
9.
DaviesD S (1977) Drug metabolism in man. In: Drug Metabolism: from Microbe to Man. Edited by ParkeD V and SmithR L (Taylor & Francis, London) pp 357–368
10.
DaviesD S & ThorgeirssonS S (1971a) Mechanisms of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Annals of the New York Academy of Sciences179, 411
11.
DaviesD S & ThorgeirssonS S (1971b) Individual differences in the plasma half-lives of lipid soluble drugs in man. Acta Pharmacologica et Toxicologica29 (Suppl 3), 181
12.
OrmeM, HoltB L J, HughesDRV, BulpittC J, DraffanG H, ThorgeirssonS S, WilliamsF & DaviesDS (1976) Plasma concentrations of phenylbutazone and its therapeutic effect–studies in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology3, 185
13.
VesellE F & PageJ G (1968) Genetic control of drug levels in man: phenylbutazone. Science159, 1479
14.
WagnerJ G, NorthamJ I, AlwayC D & CarpenterO S (1965) Blood levels of drug at the equilibrium state after multiple dosing. Nature207, 1301
15.
WhitakerJ A & PriceEvans D A (1970) Genetic control of phenylbutazone metabolism in man. British Medical Journal4, 323
